Double Bond Pharmaceutical about to sell Temodex in Latin America
Double Bond Pharmaceutical and CLOSTER PHARMA S.A.S (Colombia) have signed a distribution agreement for Temodex in Mexico, Brazil, Colombia, Peru, Ecuador and Costa Rica. The distribution will be carried out by Double Bond Pharmaceuticals wholly owned subsidiary Drugsson AB. Temodex will be registered in respective countries and/or sold by licence.
“There is a lot of interest in Temodex in different parts of the world, and we are pleased that we can provide doctors of brain cancer patients with our innovative product,” commented Igor Lokot, CEO of Double Bond Pharmaceutical, “Latin America is a big market and could generate a lucrative business for Drugsson AB.”
More about Temodex
Temodex, which is a locally acting formulation of temozolomide developed by RI PCP in Minsk, Belarus, is registered for marketing as the first-line treatment of glioblastoma within Belarus since 2014. Temodex was acquired by DBP in autumn 2015 and is now being prepared to pass through all the tests and trials required for registration within the EU and globally.
This information is information that Double Bond Pharmaceutical International AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 28 of September 2018.
Full Company Name:
Double Bond Pharmaceutical International AB (publ)
Stock short name:
Share ISIN code:
For more info, contact
Igor Lokot, CEO
Follow us on:
Information on Double Bond Pharmaceutical International AB
DBP is a pharmaceutical company with the primary focus on development of therapies against cancer based on the company’s own developed drug delivery technology BeloGal®. The company was granted Orphan Drug Designation status by European Medicines Agency (EMA) in June 2015 for its first product, SA-033, for treatment of hepatoblastoma. Double Bond Pharmaceutical acquired rights to Temodex, a drug registered in Belarus for treatment of brain tumours, in October 2015, and was granted Orphan Drug Designation status by EMA for in July 2016 for this formulation of temozolomide for the treatment of glioma. The formulation is now being further developed for registration in EU and globally and has a working name SI-053 in DBP pipeline.